Joseph Sullivan shared a post.
Jc Sullivan shared a post.
Comments
Joseph Sullivan do it
Suggested Post
Can a new anticancer agent address unmet needs in multiple myeloma? The FDA thinks so.
Karyopharm’s KPT-330 was recently granted a Fast Track designation by the FDA for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy.
Karyopharm’s KPT-330 was recently granted a Fast Track designation by the FDA for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy.
targetedonc.com
Selinexor was recently granted a Fast Track designation by the FDA for…
https://www.facebook.com/
No comments:
Post a Comment